Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Their lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.

Arkuda Therapeutics

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Michael J. Fox Foundation

Pfizer Venture Investments

Mission BioCapital

Atlas Venture

Tekla Capital Management

Pivotal bioVenture Partners

Surveyor Capital

Cormorant Asset Management

Eli Lilly

This week at the Alzheimer's Association® International Conference, Arkuda Therapeutics will present preclinical data on lead development candidate ARKD-104, a novel oral therapeutic in development for the treatment of GRN-related frontotemporal dementia. The study showed treatment with ARKD-104 markedly increased progranulin levels – critical to restoring lysosomal function in not only FTD-GRN but in other neurodegenerative diseases. Learn more: https://lnkd.in/enX_JJcg

#progranulin #granulin #lysosome #endFTD #Alzheimers

Congrats to Thomas Kukar's lab (+ Arkuda team members Chris Holler, Ph.D., Bonne Thompson, Giuseppe Astarita, and Jean-François Blain) on this critically important work demonstrating the important role that granulins play in FTD. 

The team at Arkuda Therapeutics continues to advance drug candidates which modulate both progranulin and granulins towards clinical studies, with the goal of someday offering novel treatments for FTD and other neurodegenerative diseases. 

#granulins #ftd #therapeutics #neurodegeneration #neurodegenerativediseases

https://lnkd.in/gmEx-CQb

Congratulations to Raymond Hurst and the rest of the Arkuda Therapeutics team for a great presentation at #adpd2023, "Therapeutic Potential of ARKD-104 for Treatment of Frontotemporal Dementia and Other Neurodegenerative Diseases"

Wishing everyone a happy International Women's Day!

Today and every day we celebrate the incredible achievements of women in different aspects of life all over the world.  We are committed to an inclusive workplace which recognizes the importance of collective activism in driving sustainable change, and aspire towards a world in which we all #EmbraceEquity.

 #IWD2023

COM:ARKUDATX

Arkuda Therapeutics

People Not Available